2. Apoptosis MAPK/ERK Pathway
  3. RIP kinase Mixed Lineage Kinase Necroptosis
  4. SZM-1209

SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects.

For research use only. We do not sell to patients.

SZM-1209 Chemical Structure

SZM-1209 Chemical Structure

CAS No. : 2919801-86-6

Size Price Stock Quantity
1 mg USD 195 Get quote 3 - 4 weeks 4 - 5 weeks 2 - 3 weeks
5 mg USD 735 Get quote 3 - 4 weeks 4 - 5 weeks 2 - 3 weeks
10 mg   Get quote  
50 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

SZM-1209 Related Antibodies

Top Publications Citing Use of Products

View All RIP kinase Isoform Specific Products:

View All Isoforms
RIPK1 RIPK2 RIPK3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects[1].

IC50 & Target

RIPK1

85 nM (Kd)

RIPK3

>10000 nM (Kd)

In Vitro

SZM-1209 blocks necroptosis in a dose-dependent manner[1].
SZM-1209 (0-1 μM, 6 h) specifically inhibits phosphorylation of RIPK1-RIPK3-MLKL necroptosis signaling[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SZM-1209 Related Antibodies

Western Blot Analysis[1]

Cell Line: HT-29 cells
Concentration: 0.1, 0.5, and 1 μM
Incubation Time: 6 h
Result: SZM-1209 at 1 μM completely inhibited phosphorylation of both RIPK1 and RIPK3 in 2-6 h, and subsequently inhibited the phosphorylation of downstream MLKL.
In Vivo

SZM-1209 (25-100 mg/kg, IG) can reverse mouse deaths with significant anti-inflammatory effects in a mTNF-α-induced systemic inflammatory response syndrome (SIRS) model[1].
SZM-1209 (25-100 mg/kg, IP) significantly alleviates ALI (acute lung injury) by reducing pulmonary edema and pathological damage[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (female, 6-8 weeks old, mTNF-α (intravenous injection)-induced SIRS model)[1]
Dosage: 25, 50, and 100 mg/kg
Administration: Intragastric administration
Result: Dose-dependently improved survival rates of the SIRS mice to 30, 90, and 100%. Could effectively protect against mTNFα-induced SIRS in vivo. Serum levels of IL-6 and IL-1β were significantly decreased.
Animal Model: C57BL/6J mice (female, 6-8 weeks old, NNK (HY-126477) (65 mg/kg) short-term intratracheal exposure-induced ALI model)[1]
Dosage: 25, 50, and 100 mg/kg
Administration: IP
Result: Exhibited lower levels of IL-6 and TNF-α in BALF than those of model mice. Inhibited the expression of inflammatory genes of IL-6 and TNF-α in lung tissues of mice at a mRNA level. Significant reduced phosphorylation of RIPK1, and also completely blocked at a high dose of 100 mg/kg in lung tissue of ALI model mice.
Molecular Weight

696.71

Formula

C31H29F5N4O5S2
CAS No.
SMILES

CCS(=O)(NC1CCC(CC1)C(NC2=NC3=C(S2)C=C(C(F)=C3)OC4=CC=C(C(NC(CC5=CC=CC(C(F)(F)F)=C5)=O)=C4)F)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SZM-1209 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SZM-12092919801-86-6SZM1209SZM 1209RIP kinaseMixed Lineage KinaseNecroptosisReceptor-interacting protein kinasesRIPKMLKsAcute lung injuryacute respiratory distress syndromeALI/ARDSHT-29 cellsSIRSsystemic inflammatory response syndromeMLKL phosphorylationL929 cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SZM-1209
Cat. No.:
HY-149052
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.